5 completed, 3 not yet recruiting, 2 enrolling by invitation, 2 terminated. 4 Phase 1, 4 Phase 2, 2 Not applicable, 2 Phase 3.
Follow PAH: new trials by email Literature Review of PAH trials Research Report on PAH
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome Sotatercept - Congenital Heart Disease (CHD), Eisenmenger Syndrome | Phase 2 | Not yet recruiting | Philipps University Marburg | 40 | 2026-09-01 | 2026-03-27 |
| Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension OMega 3 - PAH | Not applicable | Not yet recruiting | University Hospital, Strasbourg, France | 22 | 2026-07-01 | 2026-07-13 |
| TSPO Endothelial - EMPATHY XBD173 - PAH | Phase 1 | Enrolling by invitation | Imperial College London | 6 | 2026-05-13 | 2026-07-13 |
| Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients Comprehensive Pulmonary Rehabilitation Program, Standard Pulmonary Rehabilitation - PAH, CTEPH | Not applicable | Not yet recruiting | Beijing Chao Yang Hospital | 84 | 2025-05-20 | 2025-05-15 |
| Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg Macitentan and Tadalafil film-coated tablets, PrOpsynvi® macitentan and tadalafil film-coated tablets - PAH | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 30 | 2024-05-14 | 2024-08-14 |
| Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg Macitentan and Tadalafil, PrOpsynvi® Film-Coated Tablets - PAH | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 30 | 2024-05-10 | 2024-09-19 |
| Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension Treprostinil via implanted pump - Pulmonary Arterial Hypertension, PAH | Unknown | University Medicine Greifswald | 30 | 2020-03-01 | 2020-03-16 | |
| A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Ralinepag - PAH, Pulmonary Hypertension | Phase 3 | Enrolling by invitation | United Therapeutics | 1000 | 2019-09-23 | 2026-10-06 |
| CXA-10 Study in Subjects With Pulmonary Arterial Hypertension CXA-10 - PAH | Phase 2 | Terminated | Complexa, Inc. | 33 | 2019-08-09 | 2020-08-26 |
| A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients Ralinepag, Placebo - PAH, Pulmonary Hypertension | Phase 3 | Completed | United Therapeutics | 687 | 2019-01-24 | 2026-06-16 |
| PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH) 75mg CXA-10, 150mg CXA-10, Placebo - PAH | Phase 2 | Terminated | Complexa, Inc. | 69 | 2018-08-01 | 2020-08-10 |
| Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years oral treprostinil - PAH | Phase 2 | Completed | United Therapeutics | 32 | 2014-12-18 | 2025-03-30 |
| Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers TransCon PEG treprostinil - PAH | Phase 1 | Withdrawn | United Therapeutics | 2014-07-01 | 2014-08-07 | |
| Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib PAH | Withdrawn | The Cleveland Clinic | 2010-08-01 | 2014-02-04 | ||
| Pulmonary Hypertension and Imatinib PAH | Completed | The Cleveland Clinic | 130 | 2010-03-01 | 2014-02-04 |
Pulmonary Arterial Hypertension (6) · Cardiovascular Diseases (4) · Connective Tissue Diseases (4) · Familial Primary Pulmonary Hypertension (4) · Hypertension (4) · Hypertension, Pulmonary (4) · Lung Diseases (4) · Vascular Diseases (4) · Respiratory Tract Diseases (2) · Eisenmenger Complex (1) · Heart Defects, Congenital (1) · Inflammation (1)
Respiratory Tract Diseases (4) · Skin and Connective Tissue Diseases (4) · Hypertension, Pulmonary (2) · Lung Diseases (2) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Heart Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
CXA-10 (2) · macitentan (2) · ralinepag (2) · ACE-011 (1) · Docosahexaenoic Acids (1) · N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl)acetamide (1) · Tadalafil (1) · treprostinil (1)
United Therapeutics (4) · Complexa, Inc. (2) · Humanis Saglık Anonim Sirketi (2) · The Cleveland Clinic (2) · Beijing Chao Yang Hospital (1) · Imperial College London (1) · Philipps University Marburg (1) · University Hospital, Strasbourg, France (1) · University Medicine Greifswald (1)
United States (8) · United Kingdom (5) · Germany (3) · Argentina (2) · Australia (2) · Austria (2) · Belgium (2) · Brazil (2) · Bulgaria (2) · Canada (2) · Chile (2) · China (2) · Croatia (2) · Czechia (2) · Denmark (2)
Theo Danoff, MD (2) · Dunbar Ivy, MD (1) · Kewal Asosingh, M.S., Ph.D (1) · Kewal Asosingh, Ph.D (1) · Martin Wilkins (1) · Stephan Rosenkranz, Prof. Dr. (1)